Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 3/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.41 |
| ▸ | MMP1 | P03956 | 2/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26022063 | 0.88 | TDP1 (0.46) | MAPK1MMP3EPHX2TDP1S1PR1 | |
| SCHEMBL26022066 | 0.86 | TDP1 (0.50) | MAPK1MMP3EPHX2TDP1S1PR1 | |
| SCHEMBL30748417 | 0.76 | MMP13 (0.60) | MMP3GAAMMP13MMP1MMP9 | |
| SCHEMBL6243951 | 0.76 | TDP1 (0.59) | MAPK1MMP3EPHX2TDP1S1PR1 | |
| SCHEMBL6947559 | 0.75 | MAPK1 (0.57) | MAPK1MMP3EPHX2TDP1S1PR1 | |
| SCHEMBL25902045 | 0.75 | TDP1 (0.58) | MAPK1MMP3EPHX2TDP1S1PR1 | |
| SCHEMBL6947554 | 0.73 | TDP1 (0.56) | MAPK1MMP3EPHX2TDP1S1PR1 | |
| SCHEMBL7450680 | 0.73 | CA12 (0.67) | MAPK1MMP3EPHX2TDP1 | |
| SCHEMBL6954857 | 0.73 | TDP1 (0.56) | MAPK1MMP3EPHX2TDP1S1PR1 | |
| SCHEMBL8509157 | 0.73 | GAA (0.56) | MAPK1MMP3EPHX2TDP1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | MAPK1 1518/4885MMP3 479/4885EPHX2 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.